Αρχική World News Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer World News Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer Από Ogkologos - 7 Απριλίου, 2026 378 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POLAR study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Clinics Offering “Mammoglam” Services to Encourage More Women to Get Mammograms 12 Ιουνίου, 2019 Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... 6 Ιουνίου, 2024 Living With Metastatic Breast Cancer: How I Reinvented Myself 30 Οκτωβρίου, 2020 No Benefit for Post-operative Radiotherapy in Non-small-cell Lung Cancer [ESMO2020 Press... 20 Σεπτεμβρίου, 2020 Φόρτωση περισσοτέρων HOT NEWS ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... Want to learn more about Sulforaphanes? Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... Lymph Node Biopsies Are Unnecessary For Early-Stage Breast Cancer Patients, Study...